How will the Growth Unfold for Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Leaders: Pfizer, Inc., Valeant Pharmaceuticals Inc., Novartis AG, Bayer AG, Sanofi S.A., GlaxoSmithKline plc.

The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.

The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.

Competition Analysis

The competitive landscape of benign prostatic hyperplasia prostate treatment market involves some of the industry behemoths, posing strong competition facing other smaller players. The report covers Pfizer, Inc., Valeant Pharmaceuticals Inc., Novartis AG, Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristol-Myers Squibb and Company, Teva Pharmaceutical Industries Ltd, Mylan N.V., Merck & Co., Cardinal Health Inc., and Eli Lilly and Company among others.

Request to Download a Sample Copy of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1664

Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment

The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.

Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.

Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets

Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.

Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.

On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.

UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market

Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasia prostate treatment. The UroLift® System is permanently implanted via a transurethral outpatient procedure and predominantly relieves prostate obstruction, which is one of the primary symptoms of benign prostatic hyperplasia. The company has also declared insurance coverage for UroLift® System. While the coverage is being provided by Humana, it is most likely to improve awareness about increasing availability and broadening access of minimally invasive treatment methods in urological conditions such as benign prostatic hyperplasia. This in turn will encourage adoption of UroLift® System among patients seeking effective benign prostatic hyperplasia prostate treatment.

Need More Detailed Information about Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-1664

A majority of patients with enlarged prostate continue to perceive medication and surgery as the only available treatment alternatives. However, an increasing number of physician recommendations is advocating the use of The UroLift® System as it eliminates side effects associated with other conventional options of benign prostatic hyperplasia prostate treatment.

Benign Prostatic Hyperplasia Bph And Prostate Treatment Market Reports - Table of Contents
1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. Technology Roadmap

1.4. FMI Analysis and Recommendations

2. Market Introduction

2.1. Market Introduction

2.2. Market Taxonomy

2.3. Market Definition

2.4. Inclusions and Exclusions

3. Benign Prostatic Hyperplasia Prostate Treatment Market Opportunity Analysis

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

4. Market Background

4.1. Market Dynamics

4.1.1. Drivers

4.1.2. Restraints

4.1.3. Key Trends

5. Key Inclusions

5.1. Pipeline Analysis

5.2. Prevalence and Treatment Seeking Population Analysis

6. Global Economic Outlook

6.1. Gross Domestic Product by Region & Country, 2006 – 2021

7. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region

7.1. Introduction / Key Findings

7.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013–2017

7.2.1. North America

7.2.2. Latin America

7.2.3. Europe

7.2.4. South Asia

7.2.5. East Asia

7.2.6. Oceania

7.2.7. The Middle East and Africa

7.2.8. Emerging Countries

7.3. Market Size (US$ Mn) Forecast By Region, 2018–2028

7.4. Market Attractiveness Analysis by Region

8. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Treatment Type

8.1. Introduction

8.2. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017

8.2.1. Drugs

8.2.1.1. Alpha Blockers

8.2.1.2. 5-alpha Reductase Inhibitors

8.2.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors

8.2.1.4. Muscarinic Receptor Antagonist (MRA)

8.2.1.5. Combination Drug

8.2.2. Device

8.2.2.1. Prostatic Stents

8.2.2.2. Suture Base Implant Systems

8.2.2.3. Transurethral RF Thermal Therapy Devices

8.3. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028

8.4. Market Attractiveness Analysis by Treatment Type

Request to Browse Report Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1664

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Blog: http://keepfacts.com/

Web: https://www.futuremarketinsights.com/

This release was published on openPR.